Dextromethorphan and Diabetic Neuropathy

Criner, Tonya M; Perdun, Carla S

doi:10.1345/aph.18296

Cited by 9 publications

(3 citation statements)

References 10 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Up to 450 bed-days were therefore saved as a result of domiciliary initiation. Overall concordance rate was 84.1% (n = 111) with little difference in dropout rate between home and hospital initiation (17.3% (n = 12) vs 14.2% (n = 9)), similar to existing data for the outpatient department (82% concordance)1 and hospital initiation (75% and 97% concordance) 2 3. Patients with chronic obstructive pulmonary disease were least likely to tolerate domiciliary initiation.…”

Section: P12 Retrospective Evaluation Of Home Initiation For Long-tersupporting

confidence: 67%

NIV in clinical practice: view from the frontline

2009

Thorax

View full text Add to dashboard Cite

Section: P12 Retrospective Evaluation Of Home Initiation For Long-tersupporting

confidence: 67%

NIV in clinical practice: view from the frontline

2009

Thorax

View full text Add to dashboard Cite

“…The stimulation of NMDA receptors can result in the stimulation of the second-order neurons in the spinal cord leading to an influx of calcium. Two studies have analyzed the effectiveness of dextromethorphan in diabetic painful neuropathy and postherpetic neuralgia [73,74]. Both studies showed the dextromethorphan reduced the pain intensity in diabetic painful neuropathy but not in postherpetic neuralgia.…”

Section: Dextromethorphanmentioning

confidence: 99%

New treatments for diabetic neuropathy: Symptomatic treatments

Krishnan

Rayman

2003

Curr Diab Rep

View full text Add to dashboard Cite

Painful diabetic neuropathy is a common distressing and challenging condition. The mechanism or mechanisms involved in its pathogenesis continue to elude clinical scientists. As with other conditions of painful distal symmetrical neuropathic conditions, pain relief involves the use of a variety of analgesic and neuroleptic drugs, aimed at reducing either central responses to painful stimuli or at dampening spontaneous irritability of affected neurons. More recently, several therapies directed at putative pathologic mechanisms specific to painful diabetic neuropathy have evolved. These include vasodilators, protein kinase C beta inhibition, antioxidants, and novel aldose reductase inhibitors. Preliminary clinical studies of these therapies have at present involved small numbers of patients; however, the results have been encouraging. This article considers the clinical aspects of diagnosis and management of chronic painful diabetic neuropathy, focusing on existing and newer therapies.

show abstract

“…The available efficacy and safety data collected in these settings are insufficient, and further clinical trials are needed. Because dextromethorphan is an NMDA receptor antagonist, it has been investigated for its analgesic properties and found useful for diabetic neuropathy [19,67]. High doses were required (mean 300 mg/day).…”

Section: Dextromethorphanmentioning

confidence: 99%

Important drugs for cough in advanced cancer

Homsi

Walsh

Nelson

2001

Support Care Cancer

View full text Add to dashboard Cite

Cough is a defense mechanism that prevents the entry of noxious materials into the respiratory system and clears foreign materials and excess secretions from the lungs and respiratory tract. In advanced cancer, it is a common symptom that interferes with the patient's daily activity and quality of life. Empiric treatment with antitussive agents is often needed. Two classes of antitussive drugs are available: (1) centrally acting: (a) opioids and (b) non-opioids; (2) peripherally acting: (a) directly and (b) indirectly. Antitussive availability varies widely around the world. Many antitussives, such as benzonatate, codeine, hydrocodone, and dextromethorphan, were extensively studied in the acute and chronic cough settings and showed relatively high efficacy and safety profiles. Benzonatate, clobutinol, dihydrocodeine, hydrocodone, and levodropropizine were the only antitussives specifically studied in cancer and advanced cancer cough. They all have shown to be effective and safe in recommended daily dose for cough. In advanced cancer the patient's current medications, previous antitussive use, the availability of routes of administration, any history of drug abuse, the presence of other symptoms and other factors, all have a role in the selection of antitussives for prescription. A good knowledge of the pharmacokinetics, dosage, efficacy, and side effects of the available antitussives provides for better management.

show abstract

Dextromethorphan and Diabetic Neuropathy

Abstract: There are insufficient safety and efficacy data to justify the use of dextromethorphan for treating painful diabetic neuropathy. Further clinical trials are needed.

Cited by 9 publications

References 10 publications

NIV in clinical practice: view from the frontline

NIV in clinical practice: view from the frontline

New treatments for diabetic neuropathy: Symptomatic treatments

Important drugs for cough in advanced cancer

Contact Info

Product

Resources

About